account
They're similarly effective and safe for neovascular age-related macular degeneration, but intravitreal aflibercept might have an edge over ranibizumab in convenience, researchers say.
That's because aflibercept (Eylea, Regeneron) can be given every two months, whereas ranibizumab (Lucentis, Genentech) is given monthly.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
This article has:
- 1 view
Reactions to Eylea and Lucentis are comparable in macular degeneration -
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account